Suppr超能文献

口服阿莫西林或腹腔内注射万古霉素治疗腹膜透析患者肠球菌性腹膜炎:一项回顾性研究。

Treatment of Enterococcal Peritonitis in Peritoneal Dialysis Patients by Oral Amoxicillin or Intra-Peritoneal Vancomcyin: a Retrospective Study.

作者信息

Szeto Cheuk Chun, Ng Jack Kit-Chung, Chow Kai Ming, Kwan Bonnie Ching-Ha, Kwong Vickie Wai-Ki, Law Man-Ching, Leung Chi Bon, Li Philip Kam-To

出版信息

Kidney Blood Press Res. 2017;42(5):837-843. doi: 10.1159/000484426. Epub 2017 Oct 27.

Abstract

BACKGROUND/AIMS: Enterococcal peritonitis in peritoneal dialysis (PD) patients is associated with a high complication rate. The optimal treatment regimen of PD-related enterococcal peritonitis is controversial. The latest international guideline recommends intra-peritoneal (IP) vancomycin. Although ampicillin is often effective for systemic enterococcal infections, they have little in vitro activity when added to common PD solutions. Since oral amoxicillin achieves therapeutic drug level in the peritoneal cavity, we explore the efficacy of oral amoxicillin for enterococcal peritonitis.

METHODS

We studied 105 episodes of enterococcal peritonitis over 20 years in our unit; 43 (41.0%) were treated with oral amoxicillin, and 62 (59.0%) with IP vancomycin. Their clinical outcome was reviewed.

RESULT

The overall primary response rate to oral amoxicillin and IP vancomycin was 76.4% and 85.5%, respectively (p = 0.3). The complete cure rate of oral amoxicillin and IP vancomycin was 55.8% and 54.8%, respectively (p = 0.8). When the 5 episodes of ampicillin-resistant Enterococcus episodes were excluded, the primary response rate and complete cure rate of oral amoxicillin were 86.8% and 63.2%, respectively.

CONCLUSION

Oral amoxicillin has an excellent primary response rate and complete cure rate for PD-related peritonitis episodes caused by Enterococcus species, indicating that oral amoxicillin is a valid and convenient therapeutic option for enterococcal peritonitis episodes.

摘要

背景/目的:腹膜透析(PD)患者的肠球菌性腹膜炎并发症发生率较高。PD相关性肠球菌性腹膜炎的最佳治疗方案存在争议。最新的国际指南推荐腹腔内使用万古霉素。虽然氨苄西林对全身性肠球菌感染通常有效,但添加到常用的PD溶液中时体外活性较低。由于口服阿莫西林可在腹腔内达到治疗药物水平,我们探讨口服阿莫西林治疗肠球菌性腹膜炎的疗效。

方法

我们研究了本单位20年间105例肠球菌性腹膜炎病例;43例(41.0%)接受口服阿莫西林治疗,62例(59.0%)接受腹腔内万古霉素治疗。回顾了它们的临床结局。

结果

口服阿莫西林和腹腔内万古霉素的总体主要缓解率分别为76.4%和85.5%(p = 0.3)。口服阿莫西林和腹腔内万古霉素的完全治愈率分别为55.8%和54.8%(p = 0.8)。排除5例耐氨苄西林肠球菌病例后,口服阿莫西林的主要缓解率和完全治愈率分别为86.8%和63.2%。

结论

口服阿莫西林对肠球菌引起的PD相关性腹膜炎病例具有优异的主要缓解率和完全治愈率,表明口服阿莫西林是治疗肠球菌性腹膜炎病例的一种有效且便捷的治疗选择。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验